{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:40:10Z","timestamp":1756276810992,"version":"3.44.0"},"reference-count":9,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,10,31]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>A woman in her 40s presented with a 3-month history of lower abdominal pain and intermenstrual bleeding. Ultrasound of the pelvis disclosed a 4\u2009cm left adnexal mass. An MRI of the pelvis revealed a 2.2\u00d73.6\u00d72.4 cm solid, enhancing left ovarian mass. Due to high suspicion for malignancy, she underwent laparoscopic left salpingo-oophorectomy and resection of the tumour. Histopathology revealed papillary thyroid carcinoma in the background of struma ovarii as confirmed by thyroglobulin and thyroid transcription factor-1 positivity on immunohistochemistry. BRAF mutation analysis was negative. An ultrasound of the thyroid gland showed two low-risk nodules. An iodine-123 whole-body scan showed normal uptake in the thyroid gland. Thyroid-stimulating hormone (TSH) was 1.070 mcIU\/mL (0.450\u20134.500), and thyroglobulin was 6.8\u2009ng\/mL (1.5\u201338.5). We risk-stratified this patient as low risk for recurrence. Risk stratification of malignant struma ovarii is essential to determine suitable thyroid targeting adjuvant therapy and reduce the risk of recurrence.<\/jats:p>","DOI":"10.1136\/bcr-2022-252129","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T10:00:31Z","timestamp":1668074431000},"page":"e252129","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Papillary thyroid carcinoma in struma ovarii: management after surgery"],"prefix":"10.1136","volume":"15","author":[{"given":"Chandriya","family":"Chandran","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patamaporn","family":"Lekprasert","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Minimo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Win","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"2025082622590313000_15.11.e252129.1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.gore.2016.05.014","article-title":"Treatment and follow-up of malignant struma ovarii: regarding two cases","volume":"17","author":"Oudoux","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"2025082622590313000_15.11.e252129.2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3802\/jgo.2008.19.2.135","article-title":"Clinical characteristics of struma ovarii","volume":"19","author":"Yoo","year":"2008","journal-title":"J Gynecol Oncol"},{"key":"2025082622590313000_15.11.e252129.3","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6315"},{"key":"2025082622590313000_15.11.e252129.4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00404-021-05969-0","article-title":"Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10\u00a0years","volume":"303","author":"Addley","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"2025082622590313000_15.11.e252129.5","doi-asserted-by":"publisher","DOI":"10.5858\/134.5.786"},{"key":"2025082622590313000_15.11.e252129.6","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0887"},{"key":"2025082622590313000_15.11.e252129.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00141-0"},{"key":"2025082622590313000_15.11.e252129.8","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2011.645921"},{"key":"2025082622590313000_15.11.e252129.9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/thy.2022.0145","article-title":"Proposed risk stratification and patterns of radioactive iodine therapy in malignant struma ovarii","volume":"32","author":"Egan","year":"2022","journal-title":"Thyroid"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-252129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:59:14Z","timestamp":1756274354000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-252129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,10]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bcr-2022-252129"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-252129","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}